Humoral Immune Reconstitution with the Use of Bruton Tyrosine Kinase Inhibitor Treatment for Patients with Waldenström Macroglobulinemia
Hematology Reports · 29.10.2026 · 18 (6) · 82
DOI: 10.3390/hematolrep18060082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 29.10.2026. Verfasst von Tanim Jain und 2 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Waldenström macroglobulinemia (WM) is a B-cell lymphoma, defined by immunoglobulin M monoclonal gammopathy, lymphoplasmacytic marrow infiltration, and impaired humoral immunity with increased infections. With advances in WM treatment, Bruton tyrosine kinase inhibitors (BTKis) are increasingly used as first-line therapy. Studies show that BTKi use in chronic lymphocytic leukemia is associated with partial humoral immune reconstitution and decreased rates of infections. This study investigates whether BTKi treatment for WM is associated with a reduced risk of infectious complications compared with traditional systemic therapies.
Methods
In this single-institution retrospective analysis, we compared immunoglobulin levels and infectious complications in WM patients treated with BTKis, rituximab, or chemoimmunotherapy.
Results
Treatment of WM with BTKis was associated with an increase in serum IgA levels by 33%. Rituximab monotherapy was also associated with increased IgA (9%), but after 24 months. Patients treated with BTKis developed fewer infections, 50% compared with 68.4–71.4% of patients in other groups. Severe infections (≥grade 3) occurred most frequently in patients treated with chemoimmunotherapy. There was no correlation between development of infections and serum IgG levels or neutrophil count.
Conclusions
Results demonstrate that treatment with BTKis is associated with a decreased risk of infection over time due to partial humoral immune reconstitution, as evidenced by increasing serum IgA.
Zitieren
APA
Jain, T., Hariharan, N., & Heyman, B. (2026). Humoral Immune Reconstitution with the Use of Bruton Tyrosine Kinase Inhibitor Treatment for Patients with Waldenström Macroglobulinemia. Hematology Reports, 18(6), 82. https://doi.org/10.3390/hematolrep18060082
Vancouver
Jain T, Hariharan N, Heyman B. Humoral Immune Reconstitution with the Use of Bruton Tyrosine Kinase Inhibitor Treatment for Patients with Waldenström Macroglobulinemia. Hematology Reports. 2026;18(6):82. doi:10.3390/hematolrep18060082
BibTeX
@article{Jain2026,
author = {Jain, Tanim and Hariharan, Nisha and Heyman, Benjamin},
title = {Humoral Immune Reconstitution with the Use of Bruton Tyrosine Kinase Inhibitor Treatment for Patients with Waldenström Macroglobulinemia},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {6},
pages = {82},
doi = {10.3390/hematolrep18060082}
}
EUVIMED